Bicycle Therapeutics/BCYC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Bicycle Therapeutics

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

Ticker

BCYC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kevin Lee

Employees

284

Headquarters

Cambridge, United Kingdom

BCYC Metrics

BasicAdvanced
$1.5B
Market cap
-
P/E ratio
-$4.45
EPS
0.87
Beta
-
Dividend rate
$1.5B
0.87487
$28.91
$12.54
387K
10.421
8.651
8.651
-34.46%
-56.13%
-38.51%
36.643
4.282
168.47%
-6.72%
37.44%

What the Analysts think about BCYC

Analyst Ratings

Majority rating from 11 analysts.
Buy

BCYC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-135.89% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
267.92%
Net income
-$27M
-45.92%
Profit margin
-135.89%
-85.30%

BCYC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 50.15%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.41
-$1.26
-$1.16
-$0.62
-
Expected
-$1.29
-$1.17
-$1.23
-$1.24
-$1.14
Surprise
9.02%
7.56%
-5.95%
-50.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Bicycle Therapeutics stock?

Bicycle Therapeutics (BCYC) has a market cap of $1.5B as of June 18, 2024.

What is the P/E ratio for Bicycle Therapeutics stock?

The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of June 18, 2024.

Does Bicycle Therapeutics stock pay dividends?

No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of June 18, 2024.

When is the next Bicycle Therapeutics dividend payment date?

Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.

What is the beta indicator for Bicycle Therapeutics?

Bicycle Therapeutics (BCYC) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Bicycle Therapeutics stock price target?

The target price for Bicycle Therapeutics (BCYC) stock is $41.33, which is NaN% below the current price of $. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Bicycle Therapeutics stock

Buy or sell Bicycle Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing